Tempol treatment did not reduce obesity in FXR-null mice indicating that intestinal FXR signaling contributed to the reduced obesity effect of tempol suggesting biochemical cross-talk between the microbiota, FXR and metabolic disorders such as obesity. The gene discussed is NR1H4; the disease is obesity due to melanocortin 4 receptor deficiency.